Karo Bio AB: Successful Phase II Study Expands the Potential For Eprotirome in Dyslipidemia Treatment

STOCKHOLM, Sweden--(BUSINESS WIRE)--Regualtory News: Karo Bio (STO:KARO) has successfully completed a 10 week phase IIb study with eprotirome given to dyslipidemia patients undergoing treatment with the cholesterol absorption inhibitor ezetimibe. Eprotirome induced a statistically significant and clinically relevant lowering of serum LDL-cholesterol, triglycerides and lipoprotein(a) and was safe and well tolerated. Data show that eprotirome in combination with ezetimibe can become an important treatment option for patients with dyslipidemia.